AI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live · FMP| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.31% | -0.61% | +2.74% | -9.75% | +6.83% | +9.52% | +23.43% | +74.72% | +105.80% | +54.41% | +21143.34% |
Aftermarket
Live · FMPLast trade
$134.50
1 sh
Bid
$133.00
10 sh
Ask
$137.50
22 sh
Spread
$4.500
Fair value
Football field →Weighted blend
$121.89
-9.33% vs spot
Recommendation
Underweight
19 of 20 methods
Method spread
5bull13bear
±5% threshold
Analyst PT consensus: $161.88 (+20.42%)
Total assets
$59.02B
Total debt
$24.59B
Cash & equiv
$7.56B
Operating CF
$10.02B
Free cash flow
$9.46B
Buybacks
-$1.92B
Analyst view
DB · price_targets + analyst_gradesConsensus target
$161.88
+20.42% upside
Low
$133.00
Median
$162.50
High
$180.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Gilead Sciences, Inc. (GILD) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 12, 2026
- Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcriptseekingalpha.com·May 08, 2026
- Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com·May 07, 2026
- Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHFbusinesswire.com·May 05, 2026
- Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metricszacks.com·May 04, 2026
- Can You Sue A Drug Company For Not Inventing Faster?forbes.com·May 04, 2026
- Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?zacks.com·May 01, 2026
- Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferencesbusinesswire.com·May 01, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $7.93B | $2.18B | $1.74 |
| Q3 Sep 2025 | $7.77B | $3.05B | $2.43 |
| Q2 Jun 2025 | $7.08B | $1.96B | $1.56 |
| Q1 Mar 2025 | $6.67B | $1.32B | $1.04 |
| Q4 Dec 2024 | $7.57B | $1.78B | $1.42 |
| Q3 Sep 2024 | $7.55B | $1.25B | $1.00 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
O'Day Daniel Patrick director, officer: Chairman & CEO | Sell | 6,950 | $895.07K | Apr 28, 2026 |
O'Day Daniel Patrick director, officer: Chairman & CEO | Sell | 3,050 | $396.53K | Apr 28, 2026 |
Mercier Johanna officer: Chief Comm & Corp Aff Officer | Sell | 3,000 | $422.88K | Apr 15, 2026 |
Dickinson Andrew D officer: Chief Financial Officer | Sell | 3,000 | $422.88K | Apr 15, 2026 |
O'Day Daniel Patrick director, officer: Chairman & CEO | Sell | 10,000 | $1.37M | Mar 27, 2026 |
Dickinson Andrew D officer: Chief Financial Officer | Sell | 3,000 | $432.69K | Mar 16, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $29.44B | $11.82B | $8.51B | $6.78 | +28.90% |
| FY 2024 | $28.75B | $1.66B | $480M | $0.38 | +1.67% |
| FY 2023 | $27.12B | $7.61B | $5.67B | $4.50 | +20.89% |
| FY 2022 | $27.28B | $7.33B | $4.59B | $3.64 | +16.83% |
| FY 2021 | $27.31B | $9.92B | $6.23B | $4.93 | +22.80% |